Ocuphire Pharma Investor Day Presentation Deck

P 92 VEGA-1: >10 Letter Gain in DCNVA with Nyxol at 12 Hours Nyxol as a Single Drop Provides a Clinically Meaningful >10 Letter Gain Compared to Placebo Percent of Subjects (%) 70% 60% 50% 40% 30% 20% 10% 0% VEGA-1 Phase 2 Trial Percent of Subjects with ≥ 10 Letters Binocular Photopic DCNVA Improvement from Baseline Placebo (n=74) Nyxol (n=73) 28% n=74 p=0.005 53% n=73 > 10 Letters DCNVA Letters Gained at 12 Hours After Nyxol Dosing Nyxol showed promising ≥10 letter near vision gain at 12 hours Source: VEGA-1 TLR Table 14.2.1.7 Percent of Subjects with Improvement in Photopic DCNVA at 0 Minutes for Nyxol and Placebo Treated Subjects (PP Population) Ocuphire PHARMA

View entire presentation